New Delhi: The central and state drug regulatory bodies have banned the licences of numerous production facilities and revoked the product approvals of a few others, all on the grounds of quality.
The decision by the DGCA was taken after it examined 76 enterprises across 20 states and union territories, with close to 203 firms being identified for review.